Antibodies have long been recognised as potent vectors for carrying diagnostic medical
radionuclides, contrast agents and optical probes to diseased tissue for imaging. The area of …

Identification of cancer cell–surface biomarkers and advances in antibody engineering have
led to a sharp increase in the development of therapeutic antibodies. These same advances …

Antibody technology has transformed drug development, providing robust approaches to
producing highly targeted and active therapeutics that can routinely be advanced through …

Summation The identification of tumor tissue biomarkers has led to the production,
validation, and Food and Drug Administration-approval of a number of antibody-based …

Inert and stable radiolabeling of monoclonal antibodies (mAb), antibody fragments, or
antibody mimetics with radiometals is a prerequisite for immuno-PET. While radiolabeling is …

Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

Positron emission tomography (PET) and single-photon emission computed tomography
(SPECT) are molecular imaging strategies that typically use radioactively labeled ligands to …

Combining the specificity of tumor-targeting antibodies with the sensitivity and quantification
offered by positron emission tomography (PET) provides tremendous opportunities for …

More than 50 monoclonal antibodies (mAbs), including several antibody–drug conjugates,
are in advanced clinical development, forming an important part of the many molecularly …

Recent advances in molecular characterization of tumors have made possible the
emergence of new types of cancer therapies where traditional cytotoxic drugs and …